Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain; Centro de Investigación Médica Aplicada (CIMA), University of Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain; Centro de Investigación Médica Aplicada (CIMA), University of Navarra, Pamplona, Spain.
Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188953. doi: 10.1016/j.bbcan.2023.188953. Epub 2023 Jul 10.
Protein phosphatase 2A (PP2A) inactivation is common in cancer, leading to sustained activation of pro-survival and growth-promoting pathways. PP2A consists of a scaffolding A-subunit, a catalytic C-subunit, and a regulatory B-subunit. The functional complexity of PP2A holoenzymes arises mainly through the vast repertoire of regulatory B-subunits, which determine both their substrate specificity and their subcellular localization. Therefore, a major challenge for developing more effective therapeutic strategies for cancer is to identify the specific PP2A complexes to be targeted. Of note, the development of small molecules specifically directed at PP2A-B56α has opened new therapeutic avenues in both solid and hematological tumors. Here, we focus on the B56/PR61 family of PP2A regulatory subunits, which have a central role in directing PP2A tumor suppressor activity. We provide an overview of the mechanisms controlling the formation and regulation of these complexes, the pathways they control, and the mechanisms underlying their deregulation in cancer.
蛋白磷酸酶 2A(PP2A)失活在癌症中很常见,导致促生存和促进生长的途径持续激活。PP2A 由支架 A 亚基、催化 C 亚基和调节 B 亚基组成。PP2A 全酶的功能复杂性主要源于调节 B 亚基的巨大库,这些亚基决定了它们的底物特异性和亚细胞定位。因此,开发更有效的癌症治疗策略的主要挑战是确定要靶向的特定 PP2A 复合物。值得注意的是,专门针对 PP2A-B56α 的小分子的开发为实体瘤和血液系统肿瘤开辟了新的治疗途径。在这里,我们重点介绍 PP2A 调节亚基的 B56/PR61 家族,它们在指导 PP2A 肿瘤抑制活性方面发挥着核心作用。我们提供了这些复合物的形成和调节机制、它们控制的途径以及它们在癌症中失调的机制的概述。